These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 19758759

  • 21. Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer.
    Minisini AM, Di Loreto C, Mansutti M, Artico D, Pizzolitto S, Piga A, Puglisi F.
    Cancer Lett; 2005 Jun 16; 224(1):133-9. PubMed ID: 15911109
    [Abstract] [Full Text] [Related]

  • 22. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
    Uggla B, Tina E, Nahi H, Paul C, Höglund M, Sirsjö A, Tidefelt U.
    Int J Oncol; 2007 Jul 16; 31(1):153-60. PubMed ID: 17549416
    [Abstract] [Full Text] [Related]

  • 23. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
    Tinari N, Lattanzio R, Natoli C, Cianchetti E, Angelucci D, Ricevuto E, Ficorella C, Marchetti P, Alberti S, Piantelli M, Iacobelli S.
    Clin Cancer Res; 2006 Mar 01; 12(5):1501-6. PubMed ID: 16533774
    [Abstract] [Full Text] [Related]

  • 24. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A.
    Hum Pathol; 2006 Oct 01; 37(10):1333-43. PubMed ID: 16949920
    [Abstract] [Full Text] [Related]

  • 25. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
    Zhou Z, Guan H, Kleinerman ES.
    Mol Cancer Res; 2005 May 01; 3(5):271-5. PubMed ID: 15886298
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients.
    Zhu L, Li YF, Chen WG, He JR, Peng CH, Zhu ZG, Li HW.
    Chin Med J (Engl); 2008 Oct 20; 121(20):1965-8. PubMed ID: 19080257
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. HER-2 and topoisomerase II as predictors of response to chemotherapy.
    Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B.
    J Clin Oncol; 2008 Feb 10; 26(5):736-44. PubMed ID: 18258981
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Immunohistochemical study on topoisomerase IIalpha, Ki-67 and cytokeratin-19 in oral lichen planus lesions.
    Mattila R, Alanen K, Syrjänen S.
    Arch Dermatol Res; 2007 Jan 10; 298(8):381-8. PubMed ID: 17072627
    [Abstract] [Full Text] [Related]

  • 33. Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies.
    Brunello E, Brunelli M, Manfrin E, Nottegar A, Bersani S, Vergine M, Molino A, Fiorio E, Chilosi M, Gobbo S, Martignoni G, Bonetti F.
    Histopathology; 2012 Feb 10; 60(3):482-8. PubMed ID: 22168383
    [Abstract] [Full Text] [Related]

  • 34. Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites.
    Durbecq V, Di Leo A, Cardoso F, Rouas G, Leroy JY, Piccart M, Larsimont D.
    Breast Cancer Res Treat; 2003 Feb 10; 77(3):199-204. PubMed ID: 12602919
    [Abstract] [Full Text] [Related]

  • 35. Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy.
    Biesaga B, Niemiec J, Ziobro M, Wysocka J, Kruczak A.
    Breast; 2011 Aug 10; 20(4):338-50. PubMed ID: 21507646
    [Abstract] [Full Text] [Related]

  • 36. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.
    Withoff S, van der Zee AG, de Jong S, Hollema H, Smit EF, Mulder NH, de Vries EG.
    Br J Cancer; 1999 Feb 10; 79(5-6):748-53. PubMed ID: 10070864
    [Abstract] [Full Text] [Related]

  • 37. Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge.
    Munro AF, Cameron DA, Bartlett JM.
    Oncogene; 2010 Sep 23; 29(38):5231-40. PubMed ID: 20676126
    [Abstract] [Full Text] [Related]

  • 38. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA, Vellon L, Lupu R.
    Int J Mol Med; 2006 Dec 23; 18(6):1081-7. PubMed ID: 17089011
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Topoisomerase II alpha expression correlates with diminished disease-free survival in invasive breast cancer.
    O'Connor JK, Hazard LJ, Avent JM, Lee RJ, Fischbach J, Gaffney DK.
    Int J Radiat Oncol Biol Phys; 2006 Aug 01; 65(5):1411-5. PubMed ID: 16750309
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.